Zobrazeno 1 - 10
of 42
pro vyhledávání: '"W Bastain"'
Publikováno v:
Xenobiotica. 22:579-589
1. The pharmacokinetics of ticlopidine, a novel antithrombotic agent, have been investigated in 10 healthy volunteers dosed orally with the drug (250 mg 12 hourly for 21 days), to determine the basic pharmacokinetic parameters in humans, to investiga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1b53246ec4dfa7c7b10ade3ce8829ea
https://doi.org/10.3109/00498259209053121
https://doi.org/10.3109/00498259209053121
Autor:
M. Papouchado, NP Barker, Michael A. James, AG Wardleworth, K.S. Channer, H F Marlow, J D Harry, W Bastain, J V Jones
Publikováno v:
British journal of clinical pharmacology. 29(4)
1. Six healthy male human volunteers of mean age 30.8 years (range 23-37) were given single oral doses of xamoterol (20, 50, 100 or 250 mg) and placebo with a 1 week interval between each dose. Xamoterol produced a significant decrease in systolic ti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::387df3c52a0fd2dce4f7c1d886964c04
https://pubmed.ncbi.nlm.nih.gov/2139340
https://pubmed.ncbi.nlm.nih.gov/2139340
Publikováno v:
British Journal of Clinical Pharmacology. 24:527-535
1 Six male patients with alcoholic cirrhosis and seven normal control subjects were each given 80 mg twice daily of conventional propranolol for 1 week and 160 mg once daily of a long acting preparation (LA) of propranolol for 1 week. 2 Plasma propra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1139f462b1f7a16229e07b6fc28da70d
https://doi.org/10.1111/j.1365-2125.1987.tb03207.x
https://doi.org/10.1111/j.1365-2125.1987.tb03207.x
Publikováno v:
British Journal of Clinical Pharmacology. 28:718-721
The pharmacokinetics of xamoterol, a beta 1-adrenoceptor partial agonist, have been studied in patients with liver disease and a group of age- and sex-matched normal controls. No significant differences were observed after the oral administration of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb663b0691cd495663c6c5388282ff1
https://doi.org/10.1111/j.1365-2125.1989.tb03566.x
https://doi.org/10.1111/j.1365-2125.1989.tb03566.x
Publikováno v:
British Journal of Clinical Pharmacology. 24:373-379
1. In a double-blind placebo controlled four-way crossover study the effects and dose response relationships of xamoterol were studied in nine patients with angina and dyspnoea secondary to chronic left ventricular dysfunction. The duration of exerci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5897e496e8a4218792a4f4cfca7a3103
https://doi.org/10.1111/j.1365-2125.1987.tb03183.x
https://doi.org/10.1111/j.1365-2125.1987.tb03183.x
Publikováno v:
British Journal of Clinical Pharmacology. 25:165-168
1. Xamoterol is a cardioselective beta-adrenoceptor partial agonist which may have a role in the management of cardiac failure. Excretion is mainly by the renal route. 2. The kinetics of a single 200 mg oral dose of xamoterol were studied in eight el
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66a5c621f6af72ebe22d8ffe1a52aaaf
https://doi.org/10.1111/j.1365-2125.1988.tb03287.x
https://doi.org/10.1111/j.1365-2125.1988.tb03287.x
Publikováno v:
European Journal of Clinical Pharmacology. 35:183-185
The pharmacokinetics of xamoterol, a beta-adrenergic partial agonist under clinical evaluation for the treatment of mild to moderate heart failure, have been studied in 8 cardiac failure patients (NYHA Class II) of mean age 62 years. After i.v. dosin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1385960e6c3fc191d92ab50f34f2b40b
https://doi.org/10.1007/bf00609250
https://doi.org/10.1007/bf00609250
Publikováno v:
British Journal of Clinical Pharmacology. 28:67S-69S
Xamoterol has been shown in large, double-blind studies to produce benefit in patients with heart failure. Ischaemic heart disease is the commonest cause of heart failure in the Western World and many patients with heart failure also have angina pect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69b5bb4fe569391963b38aaacadeed3c
https://doi.org/10.1111/j.1365-2125.1989.tb03576.x
https://doi.org/10.1111/j.1365-2125.1989.tb03576.x
Publikováno v:
The Journal of antimicrobial chemotherapy. 24
Two human volunteer studies were performed with meropenem: a dose proportionality study of 0.25, 0.5 and 1.0 g and a probenecid interaction study. Six volunteers took part in each study. Meropenem was generally well tolerated: One volunteer was withd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db84890b7aee2e1ef0cbd47f0d6857bb
https://pubmed.ncbi.nlm.nih.gov/2808215
https://pubmed.ncbi.nlm.nih.gov/2808215
Publikováno v:
British journal of clinical pharmacology. 28
The effects of age and renal function on the pharmacokinetics and plasma concentrations of xamoterol were examined. Peak and steady state concentrations were higher in older patients, but this was due to deterioration of renal function rather than to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6019778dd60dc7b2ad1dacd44d2c2da8
https://pubmed.ncbi.nlm.nih.gov/2572257
https://pubmed.ncbi.nlm.nih.gov/2572257